Plus Therapeutics Inc
PSTV
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.68M
Close$
$-0.00
100.1% downside
Current Fair Value
100.1% downsideOvervalued by 100.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.68 Million |
|---|---|
| Enterprise Value | $7.38 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.19 |
| Beta | 1.4 |
| Outstanding Shares | 6,646,049 |
Return
| Return on Equity | -99.75% |
|---|---|
| Return on Assets | -59.91% |
| Return on Invested Capital | 151.03% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.02 |
| Price to Sales | -4.28 |
| Price to Book Ratio | 4.28 |
| Enterprise Value to Revenue | -3.01 |
| Enterprise Value to EBIT | 0.41 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 29, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
$974,000
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.88
Average shareholder expectationRevenue Estimate
$1.11 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.74%▲ 0.99% |
|---|---|
| Total Invested | $1.49M▼ 74.87% |
| Investors Holding | 22▼ 5.00% |
ESG Score
No data
About Plus Therapeutics Inc
2,018 employees
CEO: Marc Hedrick Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique na...